IL-10 -1082 G>A: A risk for prostate cancer but may be protective against progression of prostate cancer in North Indian cohort

World Journal of Urology

Volumn 27, Issue 3, 2009, Pages 389-396

  Kesarwani, Pravin ^a   Ahirwar, Dinesh Kumar ^a   Mandhani, Anil ^a   Singh, Anand Narayan ^b   Dalela, Divakar ^b   Srivastava, Anand Narain ^b   Mittal, Rama D ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^b UNIVERSITY OF LUCKNOW   (India)

Author keywords

ARMS PCR; Bone metastasis; Genepolymorphism; IL 10; Lifestyle risks; Prostate cancer

Indexed keywords

INTERLEUKIN 10;

ARTICLE; DISEASE COURSE; GENETIC POLYMORPHISM; GENETICS; HUMAN; MALE; MIDDLE AGED; PROSTATE TUMOR; RISK FACTOR;

DISEASE PROGRESSION; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 67349233541     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-008-0361-1     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA Cancer J Clin 55:74-108
2. Kolonel LN, Nomura AM, Cooney RV (1999) Dietary fat and prostate cancer: current status. J Natl Cancer Inst 91:414-428. doi: 10.1093/jnci/91.5.414
3. Hickey K, Do KA, Green A (2001) Smoking and prostate cancer. Epidemiol Rev 23:115-125
4. De Marzo AM, Platz EA, Sutcliffe S (2007) Inflammation in prostate carcinogenesis. Nat Rev Cancer 7:256-269. doi: 10.1038/nrc2090
5. Lichenstein P, Holm N, Verkasalo P et al (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78-85. doi: 10.1056/NEJM200007133430201
6. Hayes RB (2001) Gene-environment interrelations in prostate cancer. Epidemiol Rev 23:163-167
7. Yang L, Carbone DP (2004) Tumor-host immune interactions and dendritic cell dysfunction. Adv Cancer Res 92:13-27. doi: 10.1016/ S0065-230X(04)92002-7
8. Mocellin S, Marincola F, Rossi CR, Nitti D, Lise M (2004) The multifaceted relationship between IL-10 and adaptive immunity: Putting together the pieces of a puzzle. Cytokine Growth Factor Rev 15:61-76. doi: 10.1016/j.cytogfr.2003.11.001
9. Faupel-Badger JM, Kidd LC, Albanes D, Virtamo J, Woodson K, Tangrea JA (2008) Association of IL-10 polymorphisms with prostate cancer risk and grade of disease. Cancer Causes Control 19:119-124. doi: 10.1007/ s10552-007-9077-6
10. Filella X, Alcover J, Zarco MA, Beardo P, Molina R, Ballesta AM (2000) Analysis of type T1 and T2 cytokines in patients with prostate cancer. Prostate 44:271-274. doi:10.1002/ 1097-0045(20000901)44:4<271::AID-PROS2>3.0.CO;2-G
11. Spits H, De Waal Malefyt R (1992) Functional characterization of human IL-10. Int Arch Allergy Immunol 99:8-15
12. Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1-8
13. Gleason DF, Mellinger GT (1974) Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging. J Urol 111:58-64
14. Kesarwani P, Singh R, Mittal RD (2008) Association of GSTM3 Intron 6 variant with cigarette smoking, tobacco chewing and alcohol as modifier factors for prostate cancer risk. Arch Toxicol. doi: 10.1007/ s00204-008-0343-5
15. Miller SA, Dykes DD, Polesky HF (1998) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16:1215-1215. doi: 10.1093/nar/16.3.1215
16. Perrey C, Turner SJ, Pravica V, Howell WM, Hutchinson IV (1999) ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms. Transpl Immunol 7:127-128. doi: 10.1016/ S0966-3274(99)80030-6
17. Zheng LM, Ojcius DM, Garaud F et al (1996) Interleukin-10 inhibits tumor metastasis through an NK cell-dependent mechanism. J Exp Med 184:579-584. doi: 10.1084/jem.184.2.579
18. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, de Vries JE (1991) Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 174:1209-1220. doi: 10.1084/jem.174.5.1209
19. Fortis C, Foppoli M, Gianotti L et al (1996) Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett 104:1-5b. doi: 10.1016/0304-3835(96)04213-9
20. McCarron SL, Edwards S, Evans PR et al (2002) Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res 62:3369-3372
21. Sredni B, Weil M, Khomenok G (2004) Ammonium trichloro(dioxoethylene-o, o′)tellurate (AS101) sensitizes tumors to chemotherapy by inhibiting the tumor interleukin 10 autocrine loop. Cancer Res 64:1843-1852. doi: 10.1158/0008-5472.CAN-03-3179
22. Stearns ME, Fudge K, Garcia F, Wang M (1997) IL-10 inhibition of human prostate PC-3 ML cell metastases in SCID mice: IL-10 stimulation of TIMP-1 and inhibition of MMP-2/MMP-9 expression. Invasion Metastasis 17(2):62-74
23. Gibson AW, Edberg JC, Wu J, Westendorp RG, Huizinga TW, Kimberly RP (2001) Novel single nucleotide polymorphisms in the distal IL-10 promoter affect IL-10 production and enhance the risk of systemic lupus erythematosus. J Immunol 166:3915-3922
24. Eder T, Mayer R, Langsenlehner U et al (2007) Interleukin-10 [ATA] promoter haplotype and prostate cancer risk: A population-based study. Eur J Cancer 43:472-475. doi: 10.1016/j.ejca.2006.11.003
25. Andersson SO, Baron J, Bergström R, Lindgren C, Wolk A, Adami HO (1996) Lifestyle factors and prostate cancer risk: A case-control study in Sweden. Cancer Epidemiol Biomarkers Prev 5:509-513
26. Meliska CJ, Stunkard ME, Gilbert DG et al (1995) Immune function in cigarette smokers who quit smoking for 31 days. J Allergy Clin Immunol 95:901-910. doi: 10.1016/S0091-6749(95)70135-4